Array Biopharma (ARRY) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.64 --0%
EPS Growth %: -70.0%
Financial Fact:
General and administrative: 7.86M
Today's EPS Names:
SICP, FTCO, OXLC, More
EPS Growth %: -70.0%
Financial Fact:
General and administrative: 7.86M
Today's EPS Names:
SICP, FTCO, OXLC, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.11 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $35.4 million versus the consensus estimate of $32.7 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Keurig Dr Pepper price target to $40
- QuintilesIMS (Q) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- XPLR Infrastructure (XIFR) PT Lowered to $10 at Scotiabank
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
